Vorikonazol Fresenius Kabi

Voriconazole Fresenius Kabi is an antifungal medication used to treat serious fungal infections. It belongs to the triazole class and is administered intravenously. This EU-manufactured product is designed for systemic infections where oral therapy is not feasible.

Voriconazole is commonly prescribed to treat invasive fungal infections such as aspergillosis, candidemia, and other severe fungal conditions. It is also used for infections caused by Scedosporium or Fusarium species. Patients with weakened immune systems, such as those undergoing chemotherapy or organ transplants, may benefit from this medication. It works by stopping the growth of fungi.

Voriconazole may cause temporary changes in vision, including blurred or altered perception of light. Some users report sensitivity to bright light or color vision changes, which typically resolve with continued use. Mild to moderate headaches, nausea, or rash may occur during treatment. These effects are generally manageable and monitored by healthcare providers.

Voriconazole should be handled with care, especially by individuals with known allergies to azole antifungals. Pregnant or breastfeeding individuals should consult a healthcare provider before use. Regular liver function tests are recommended during treatment due to potential effects on liver enzymes. Avoid direct sunlight exposure as the medication may increase photosensitivity.

Voriconazole interacts with several medications, including certain antibiotics, anticonvulsants, and cholesterol-lowering drugs. Strong CYP3A4 inhibitors or inducers can significantly alter voriconazole levels in the blood. Alcohol may increase the risk of side effects, and grapefruit products can interfere with its metabolism. Always inform your healthcare provider about all medications and supplements being used.